Overall, our study is the first to describe the roles of SEPN1 in glioma, establishing SEPN1 as a valuable biomarker for glioma and laying the foundation for future studies on the molecular mechanisms of SEPN1 in glioma pathogenesis and the development of SEPN1-targeted therapeutic strategies. This evidence concerns the gene SELENON and glioma.